SERPINB13 is a novel RUNX1 target gene

Biochemical and Biophysical Research Communications

Volumn 411, Issue 1, 2011, Pages 115-120

  Boyapati, Anita ^a   Ren, Bing ^b   Zhang, Dong Er ^a,b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chromatin immunoprecipitation; RUNX; SERPINB13; Transcription

Indexed keywords

CATHEPSIN K; SERINE PROTEINASE INHIBITOR; SERPIN B13; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ARTICLE; ENZYME ACTIVITY; GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

CATHEPSIN K; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; SERPINS; UP-REGULATION;

EID: 79960558293     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.06.107     Document Type: Article

References (40)

1. Kamachi Y., Ogawa E., Asano M., Ishida S., Murakami Y., Satake M., Ito Y., Shigesada K. Purification of a mouse nuclear factor that binds to both the A and B cores of the polyomavirus enhancer. J. Virol. 1990, 64:4808-4819.
2. Melnikova I.N., Crute B.E., Wang S., Speck N.A. Sequence specificity of the core-binding factor. J. Virol. 1993, 67:2408-2411.
3. Meyers S., Downing J.R., Hiebert S.W. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol. Cell Biol. 1993, 13:6336-6345.
4. Thornell A., Holm M., Grundstrom T. Purification of SEF1 proteins binding to transcriptional enhancer elements active in T lymphocytes. J. Biol. Chem. 1993, 268:21946-21954.
5. Wang Q., Stacy T., Binder M., Marin-Padilla M., Sharpe A.H., Speck N.A. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. PNAS 1996, 93:3444-3449.
6. Okuda T., van Deursen J., Hiebert S.W., Grosveld G., Downing J.R. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996, 84:321-330.
7. Ichikawa M., Asai T., Saito T., Yamamoto G., Seo S., Yamazaki I., Yamagata T., Mitani K., Chiba S., Hirai H., Ogawa S., Kurokawa M. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat. Med. 2004, 10:299-304.
8. Growney J.D., Shigematsu H., Li Z., Lee B.H., Adelsperger J., Rowan R., Curley D.P., Kutok J.L., Akashi K., Williams I.R., Speck N.A., Gilliland D.G. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood 2005, 106:494-504.
9. Yamagata T., Maki K., Mitani K. Runx1/AML1 in normal and abnormal hematopoiesis. Int. J. Hematol. 2005, 82:1-8.
10. Planaguma J., az-Fuertes M., Gil-Moreno A., Abal M., Monge M., Garcia A., Baro T., Thomson T.M., Xercavins J., Alameda F., Reventos J. A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma. Cancer Res. 2004, 64:8846-8853.
11. Blyth K., Cameron E.R., Neil J.C. The RUNX genes: gain or loss of function in cancer. Nat. Rev. Cancer 2005, 5:376-387.
12. Peterson L.F., Zhang D.E. The 8;21 translocation in leukemogenesis. Oncogene 2004, 23:4255-4262.
13. Zhang D.E., Fujioka K., Hetherington C.J., Shapiro L.H., Chen H.M., Look A.T., Tenen D.G. Identification of a region which directs the monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1). Mol. Cell Biol. 1994, 14:8085-8095.
14. Frank R., Zhang J., Uchida H., Meyers S., Hiebert S.W., Nimer S.D. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene 1995, 11:2667-2674.
15. Takahashi A., Satake M., Yamaguchi-Iwai Y., Bae S.C., Lu J., Maruyama M., Zhang Y.W., Oka H., Arai N., Arai K. Positive and negative regulation of granulocyte-macrophage colony-stimulating factor promoter activity by AML1-related transcription factor, PEBP2. Blood 1995, 86:607-616.
16. Taniuchi I., Osato M., Egawa T., Sunshine M.J., Bae S.C., Komori T., Ito Y., Littman D.R. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell 2002, 111:621-633.
17. Uchida H., Zhang J., Nimer S.D. AML1A and AML1B can transactivate the human IL-3 promoter. J. Immunol. 1997, 158:2251-2258.
18. Libermann T.A., Pan Z., Akbarali Y., Hetherington C.J., Boltax J., Yergeau D.A., Zhang D.E. AML1 (CBFalpha 2) cooperates with B cell-specific activating protein (BSAP/PAX5) in activation of the B cell-specific BLK gene promoter. J. Biol. Chem. 1999, 274:24671-24676.
19. Nomura T., Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J. Med. Invest. 2005, 52:1-9.
20. Goto T., Yamaza T., Tanaka T. Cathepsins in the osteoclast. J. Electron Microsc. (Tokyo) 2003, 52:551-558.
21. Nakashima T., Pak S.C., Silverman G.A., Spring P.M., Frederick M.J., Clayman G.L. Genomic cloning, mapping, structure and promoter analysis of HEADPIN, a serpin which is down-regulated in head and neck cancer cells. Biochim. Biophys. Acta 2000, 1492:441-446.
22. Yan M., Burel S.A., Peterson L.F., Kanbe E., Iwasaki H., Boyapati A., Hines R., Akashi K., Zhang D.E. Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proc. Natl. Acad. Sci. USA 2004, 101:17186-17191.
23. Yan M., Kanbe E., Peterson L.F., Boyapati A., Miao Y., Wang Y., Chen I.M., Chen Z., Rowley J.D., Willman C.L., Zhang D.E. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat. Med. 2006, 12:945-949.
24. Li Z., Van C.S., Qu C., Cavenee W.K., Zhang M.Q., Ren B. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc. Natl. Acad. Sci. USA 2003, 100:8164-8169.
25. Huang G., Zhang P., Hirai H., Elf S., Yan X., Chen Z., Koschmieder S., Okuno Y., Dayaram T., Growney J.D., Shivdasani R.A., Gilliland D.G., Speck N.A., Nimer S.D., Tenen D.G. PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat. Genet. 2007, Epub.
26. Abts H.F., Welss T., Mirmohammadsadegh A., Kohrer K., Michel G., Ruzicka T. Cloning and characterization of hurpin (protease inhibitor 13): a new skin-specific, UV-repressible serine proteinase inhibitor of the ovalbumin serpin family. J. Mol. Biol. 1999, 293:29-39.
27. Spring P., Nakashima T., Frederick M., Henderson Y., Clayman G. Identification and cDNA cloning of headpin, a novel differentially expressed serpin that maps to chromosome 18q. Biochem. Biophys. Res. Commun. 1999, 264:299-304.
28. Giese K., Kingsley C., Kirshner J.R., Grosschedl R. Assembly and function of a TCR alpha enhancer complex is dependent on LEF-1-induced DNA bending and multiple protein-protein interactions. Genes Dev. 1995, 9:995-1008.
29. Kim W.Y., Sieweke M., Ogawa E., Wee H.J., Englmeier U., Graf T., Ito Y. Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains. EMBO J. 1999, 18:1609-1620.
30. Zhang D.E., Hetherington C.J., Meyers S., Rhoades K.L., Larson C.J., Chen H.M., Hiebert S.W., Tenen D.G. CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol. Cell Biol. 1996, 16:1231-1240.
31. Jayakumar A., Kang Y., Frederick M.J., Pak S.C., Henderson Y., Holton P.R., Mitsudo K., Silverman G.A., EL-Naggar A.K., Bromme D., Clayman G.L. Inhibition of the cysteine proteinases cathepsins K and L by the serpin headpin (SERPINB13): a kinetic analysis. Arch. Biochem. Biophys. 2003, 409:367-374.
32. Welss T., Sun J., Irving J.A., Blum R., Smith A.I., Whisstock J.C., Pike R.N., von M.A., Ruzicka T., Bird P.I., Abts H.F. Hurpin is a selective inhibitor of lysosomal cathepsin L and protects keratinocytes from ultraviolet-induced apoptosis. Biochemistry 2003, 42:7381-7389.
33. Littlewood-Evans A.J., Bilbe G., Bowler W.B., Farley D., Wlodarski B., Kokubo T., Inaoka T., Sloane J., Evans D.B., Gallagher J.A. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 1997, 57:5386-5390.
34. Brubaker K.D., Vessella R.L., True L.D., Thomas R., Corey E. Cathepsin K mRNA and protein expression in prostate cancer progression. J. Bone Miner. Res. 2003, 18:222-230.
35. Shellenberger T.D., Mazumdar A., Henderson Y., Briggs K., Wang M., Chattopadhyay C., Jayakumar A., Frederick M., Clayman G.L. Headpin: a serpin with endogenous and exogenous suppression of angiogenesis. Cancer Res. 2005, 65:11501-11509.
36. Kollet O., Dar A., Shivtiel S., Kalinkovich A., Lapid K., Sztainberg Y., Tesio M., Samstein R.M., Goichberg P., Spiegel A., Elson A., Lapidot T. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat. Med. 2006, 12:657-664.
37. Gowen M., Lazner F., Dodds R., Kapadia R., Feild J., Tavaria M., Bertoncello I., Drake F., Zavarselk S., Tellis I., Hertzog P., Debouck C., Kola I. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. 1999, 14:1654-1663.
38. Liao C., Wang X.Y., Wei H.Q., Li S.Q., Merghoub T., Pandolfi P.P., Wolgemuth D.J. Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1. Proc. Natl. Acad. Sci. USA 2001, 98:6853-6858.
39. Kim K.E., Song H., Kim T.S., Yoon D., Kim C.W., Bang S.I., Hur D.Y., Park H., Cho D.H. Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines. Oncogene 2006.
40. Muhl H., Pfeilschifter J. Interleukin-18 bioactivity: a novel target for immunopharmacological anti-inflammatory intervention. Eur. J. Pharmacol. 2004, 500:63-71.